Compare Regeneron Pharmaceuticals Inc (REGN) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tesla, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Tesla, Inc. trades at $358.8 (market cap $1.42T). The key difference: Tesla, Inc. is far larger — about 20.1× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| REGN | TSLA | |
|---|---|---|
Market Cap | $70.79B | $1.42T |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $489.88 |
52-Week Low | $545.46 | $302.63 |
Enterprise Value | $64.74B | $1.39T |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Tesla (TSLA) trades at $374.13, up 1.23% on the day, but remains in a bearish technical trend with the stock down 29% from recent highs. The company faces mixed fundamentals with declining revenue and net income margins (4% in 2025), though it maintains strong operational cash flow of $14.75B. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model to boost demand.
Tesla's investment case balances high valuation multiples (P/E 347.64) against growth bets in autonomy and energy. Near-term risks include delivery misses and competition, but analyst consensus targets $409.26, suggesting 9% upside. The stock's direction hinges on execution of AI and robotics initiatives amid a slowing auto business.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
